Amin Khan

Amin Khan has extensive work experience in the biotechnology and pharmaceutical industries. Starting in 1993, they worked as V.P. Research at West Pharmaceutical Services. Amin then joined Eli Lilly and Company in 1998 as a Distinguished Research Fellow and Executive Director. In 2008, they moved to Trinity Biosystems, where they served as President & CSO and later as CSO/COO. Amin took a sabbatical in 2010 before joining Novartis Vaccines and Diagnostics in 2011. At Novartis, they held positions including Global Head of Technical Development and MS&T and Global Head of Technical Development. In 2015, Amin joined GSK, where they worked as VP and Head of the Global Vaccines Technical R&D and later VP and Head of Vaccines R&D Acceleration Team until 2021. Following their time at GSK, they served as Chief Science Officer of Human Health at GreenLight Biosciences, Inc. From 2022 to 2023, Amin worked at Afrigen Biologics (Pty) Ltd as the Chief Science Advisor for the WHO mRNA Program. Currently, they hold the position of Executive VP and Head of R&D at Icosavax, Inc. Amin also has their own consultancy, Dr. Amin Khan LLC, where they offer advisory services in vaccines R&D.

Amin Khan holds a PhD in Pharmaceutical Sciences from the University of Nottingham.